CPA inhibitors are primarily used in the treatment of conditions related to excessive or abnormal cell proliferation, such as cancer. By inhibiting the activity of CPA enzymes, these compounds can interfere with the metabolic pathways that cancer cells rely on for growth and survival. This makes CPA inhibitors valuable in chemotherapy regimens, where they help to slow down or halt the progression of tumors. In addition to oncology, CPA inhibitors are also explored in the context of inflammatory diseases. They can modulate immune responses by affecting the production of certain mediators involved in inflammation, offering potential therapeutic benefits for conditions like arthritis or autoimmune disorders. Research is ongoing to further understand the broader applications of CPA inhibitors, including their role in combating drug resistance in cancer therapy and their potential use in combination with other treatments to enhance efficacy.